LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies:
| For further information please contact: LungLife AI, Inc. | www.lunglifeai.com |
| Paul Pagano, CEO | via investors@lunglifeai.com |
"*" indicates required fields
LungLife AI licensure/accreditation information posted here.